StreetAlpha.app
Home › Stocks › AVTX

Avalo Therapeutics, Inc. (AVTX)

Healthcare
$7.13
▼ −3.26%
LAST CLOSE · NOV 17

Avalo Therapeutics develops antibody treatments for inflammatory diseases, with its main candidate in clinical trials for hidradenitis suppurativa. It last closed at $7.13 on Nov 17, down 3.26% on the day. The average 12-month price target from 2 analysts is $15.00 (+110.4% from the last close), with a high of $20.00 and a low of $10.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in AVTX, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $1.3M, the largest $611K.

AI Auto Pilots
Is AVTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$88.7M
EPS (diluted)
−$2.26
Valuation
Market cap
$412.3M
57.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$65.0M
At Sep 30
Shareholder equity
$436.5M
Shares outstanding
57.8M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $5.4M$5.4MFY2021FY2022: $18.1M$18.1MFY2022FY2023: $1.9M$1.9MFY2023FY2024: $441K$441KFY2024FY2025: $59K$59KFY2025

From AVTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated AVTX in the past 90 days, not enough for a consensus
Average 12-month target
$15.00
▲ 110.4% upside

Based on 2 analysts who set a price target on AVTX in the past 90 days. The average target is $15.00, with a high of $20.00 and a low of $10.00, compared with the last close of $7.13.

Low $10.00Avg $15.00High $20.00
Blue marker: last close $7.13
Highest target$20.00
Average target$15.00
Lowest target$10.00
Latest rating changes
WedbushTarget lowered
Nov 6Buy$22 → $20
WedbushMaintained
Oct 23Buy$22
BTIGMaintained
Oct 23Buy$10
GuggenheimMaintained
Aug 7Buy$48
HC Wainwright & Co.Maintained
Aug 7Buy$30
DateFirmActionRatingPrice target
Nov 6WedbushTarget loweredBuy$22 → $20
Oct 23WedbushMaintainedBuy$22
Oct 23BTIGMaintainedBuy$10
Aug 7GuggenheimMaintainedBuy$48
Aug 7HC Wainwright & Co.MaintainedBuy$30
Loading…

Technical Analysis

AVTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 5% below its 20 day and 66% below its 50 day average. It is 118% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot S1 at $6.87, and the nearest resistance the Pivot at $7.14.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 11.4%/day
Key levels
$24.2752 week high+240.4%
$15.54200 day average+118.0%
$15.49100 day average+117.3%
$11.8450 day average+66.1%
$7.71Swing high (Oct 29)+8.1%
$7.5020 day average+5.2%
$7.39Pivot R1+3.6%
$7.14Pivot+0.1%
$7.13Last close
$6.87Pivot S1−3.6%
$6.5352 week low−8.4%
$6.53Swing low (Nov 6)−8.4%
Indicators
RSI (14)34.73Weak, oversold below 30Neutral
MACD-1.27Above its signal lineBullish
Stochastic44.2Middle of its rangeNeutral
ADX (14)42.3Strong downtrend
Williams %R-70.2Oversold below −80, overbought above −20Neutral
CCI (20)-40.4Oversold below −100, overbought above 100Neutral
Rate of change−1.7%Change over 10 sessionsBearish
ATR (14)$0.81Typical daily range, 11.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVTX

What happened before

See how AVTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AVTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AVTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 23 – Oct 23
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$1.3M
Largest print
$611K
Loading…

AVTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲89 buying vs 48 selling
  • ▼Held by funds -1.7 pts
  • ▲Funds holding +22
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding149127+17.3%
In funds' top 1063+100.0%
Held by funds123.9%125.6%−1.7 pts
New / increased35 / 5456 / 47−13.6%
Reduced / sold out33 / 1515 / 28+11.6%
Put/call ratio0.003.98−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVTX is in one of them and how their past AVTX trades turned out.

AVTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVTX in an article yet. Here's the latest on the wider market.

About Avalo Therapeutics

Avalo Therapeutics is a biotechnology company based in Wayne, Pennsylvania that develops treatments for inflammatory diseases driven by the immune system. Its main drug candidate, abdakibart, is an antibody that blocks IL-1β, a protein that fuels inflammation. The drug is in a Phase 2 clinical trial for hidradenitis suppurativa, a chronic skin condition that causes painful nodules and abscesses, and it is not yet approved for sale. Its intended customers are patients and the doctors who treat them.

Headquarters
Wayne, PA